ERAS-601 for Chordoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called ERAS-601 to determine its safety and effectiveness for people with chordoma, a rare type of bone cancer, particularly when the cancer worsens. Researchers aim to assess whether ERAS-601 can manage the condition without causing excessive side effects. Suitable participants have confirmed chordoma that has not responded well to other treatments and continues to progress. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Will I have to stop taking my current medications?
The trial does not specify if you must stop taking your current medications, but you cannot be on another treatment that may impact the trial's outcome within 4 weeks of starting ERAS-601. Also, you should not have had certain therapies or strong CYP3A4 inhibitors recently.
Is there any evidence suggesting that ERAS-601 is likely to be safe for humans?
Earlier studies tested ERAS-601 for safety in people with chordoma, a cancer affecting the bones at the base of the skull and spine. Research has shown that ERAS-601 is generally well-tolerated, with many patients experiencing only mild side effects. Reports of more serious side effects exist but are less common.
This trial is in the early stages (Phase 1 and 2), focusing primarily on understanding the safety of ERAS-601. Researchers closely monitor participants' responses to ensure the treatment remains safe. The progression to these trial phases indicates that ERAS-601 has shown enough promise in earlier tests to warrant further study.12345Why do researchers think this study treatment might be promising for chordoma?
Most treatments for chordoma, such as surgery and radiation, focus on removing or shrinking the tumor. However, ERAS-601 works differently by targeting specific molecular pathways that drive tumor growth, potentially slowing or stopping the disease at a more fundamental level. This targeted approach could mean fewer side effects and more effective control of the cancer. Researchers are excited about ERAS-601 because it offers a new way to tackle chordoma, which has limited treatment options and can be challenging to treat with conventional methods.
What evidence suggests that ERAS-601 might be an effective treatment for chordoma?
Research has shown that ERAS-601 may help treat advanced chordoma, a type of cancer. In one study, out of 13 people with chordoma, one person's tumor shrank. Another study found that out of 11 patients treated, two showed some improvement, though details were not provided. These early results suggest that ERAS-601 might reduce tumor size in some chordoma patients, but more research is needed to determine its overall effectiveness.12367
Who Is on the Research Team?
Mrinal Gounder, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for individuals with advanced and progressing chordoma, a type of bone cancer. Specific eligibility criteria are not provided, but typically participants must meet certain health conditions and agree to follow study procedures.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ERAS-601 40mg BID, 3-weeks on 1-week off, as monotherapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ERAS-601
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor